Summary
Ahmed Khaled is a medical oncologist and senior medical director with over a decade of combined academic and industry experience driving early- and late-stage oncology drug development. He has led programs across immuno-oncology bispecifics, checkpoint and co-stimulatory antibodies, and oncology small molecules, translating lab findings into protocols and pivotal clinical trials. At companies including Regeneron, GSK, AstraZeneca and Summit, he has overseen global development plans, medical monitoring, and translational biomarker efforts for lung cancer, mesothelioma and other solid tumors. Trained in clinical and translational research with hands-on bench experience in flow cytometry and exosome assays, he blends rigorous laboratory skills with pragmatic clinical strategy. Known for a fast-paced, learn-on-the-fly work style, he excels at navigating regulatory and operational complexity to accelerate molecules from bench to clinic. Based in Greater Philadelphia, he brings both patient-care perspective and industry leadership to complex oncology programs.
10 years of coding experience
3 years of employment as a software developer
Bachelor of Medicine Bachelor of Surgery (MBBS), Bachelor of Medicine Bachelor of Surgery (MBBS) at October 6 University
Fundamentals of Clinical Trials Certificate Medicine, Fundamentals of Clinical Trials Certificate Medicine at Harvard Medical School Professional, Corporate, and Continuing Education
Master's degree Clinical Hematology, Master's degree Clinical Hematology at Cairo University
Certificate of Clinical and Translational Research Clinical and Translational Research, Certificate of Clinical and Translational Research Clinical and Translational Research at University of Cincinnati College of Medicine